Living with PGM1-CDG & Emergency Prep
At a Glance
People with PGM1-CDG can stay active, but illness and exercise require a personalized plan to prevent low blood sugar and muscle breakdown. An updated emergency letter, sick-day instructions, glucose supplies, and clear stop signs help families act quickly.
Living with PGM1-CDG means balancing the need for an active, normal life with the reality of a metabolic “low fuel” light that can trigger at unexpected times. Because your body struggles to access stored energy, day-to-day management focuses on maintaining a steady supply of fuel and having a clear roadmap for when things go wrong [1][2].
Managing Physical Activity and Exercise
Exercise is highly beneficial for people with PGM1-CDG, but it must be approached differently than for the general population. The goal is to build fitness while avoiding rhabdomyolysis (severe muscle breakdown) [3][1]. You must get individualized metabolic and cardiac clearance before starting any exercise program.
- Aerobic Advantage: Regular, moderate aerobic activities (like walking or swimming) can actually improve your fitness and help your muscles become more resilient to injury [1]. Your care team will provide a specific plan for intensity and hydration.
- Fueling for Fitness: Some patients find that consuming carbohydrates (like a small snack or a sports drink) before activity can lower their heart rate and reduce feelings of extreme fatigue during exercise [2]. Follow your dietitian’s personalized fueling plan.
- The “Second Wind”: Some people with PGM1-CDG experience a “second wind”—a point during exercise where they suddenly feel less fatigued once the body starts burning different fuel sources. However, you should never rely on this “wind” to push through severe pain or use it as proof that exercise is safe [1][2].
- Safety Limits: Stop exercise immediately if you experience muscle locking (contractures), severe pain, chest pain, fainting, or if your urine appears dark (tea-colored) after activity [2][3].
The Essential Emergency Letter
Because PGM1-CDG is so rare, you cannot assume an ER doctor will know how to treat it. You must carry a personalized Emergency Letter from your metabolic specialist. This letter is your most important tool during an illness or accident. It should specify:
- Hypoglycemia Protocol: Instructions for rapid glucose treatment. During illness, the body needs more fuel; the letter should mandate urgent IV glucose when oral intake fails, when glucose/ketones cross specific thresholds, or when you are clinically unstable, tailored to your cardiac status [4][5].
- Adrenal Crisis Plan: If you have confirmed ACTH or adrenal deficiency, the letter must include a “stress dose” protocol for hydrocortisone. This is vital during high fevers, severe injuries, or surgery [6][4].
- Rhabdomyolysis Screening: A requirement to check Creatine Kinase (CK) levels and kidney function if you have severe muscle pain or dark urine [3].
- Cardiac Alert: A reminder for the ER team that cardiomyopathy is a risk and any heart-related symptoms require emergency assessment starting with vital signs, ECG, and labs; echocardiography is determined by these clinical findings and cardiology advice [7][8].
Sick-Day Management at Home
When you are sick with a common virus or fever, your body’s demand for energy skyrockets. You need a clinician-completed algorithm for sick days.
- Avoid Fasting: Never skip meals or snacks when sick. Even if you aren’t hungry, focus on sipping carbohydrate-rich fluids [4]. Do not force oral products if vomiting, swallowing difficulty, or altered consciousness makes it unsafe.
- Monitor Closely: Use a home glucometer to check blood sugar and ketone levels based on your patient-specific thresholds and testing frequency during an illness [6]. Know exactly when to call your metabolic team and when to go directly to the emergency department.
- Galactose Consistency: Continue taking your prescribed D-galactose doses unless your doctor specifically tells you to stop. Note that D-galactose is not a substitute for rapid glucose treatment of acute hypoglycemia [9][10].
Transitioning to Adult Care
As children with PGM1-CDG grow into adults, their care needs to move from a pediatric setting to an adult multidisciplinary team. This transition should begin in the mid-teens and involves:
- Finding Adult Specialists: You will need an adult metabolic geneticist, cardiologist, and endocrinologist who are willing to learn about this rare condition [4][11].
- Self-Management: Young adults should practice explaining their condition to others and managing their own daily galactose doses [12].
- Reproductive Counseling: Because PGM1-CDG is inherited in an autosomal-recessive pattern, adults of any gender and their partners may want preconception counseling to discuss carrier testing and sibling recurrence risks. For women with PGM1-CDG, pregnancy requires intensive monitoring of liver, heart, and clotting factors by a high-risk maternal-fetal medicine team [13].
Quality of Life
Living with a rare disease is a marathon, not a sprint. While fatigue and the “burden” of treatment (taking multiple daily doses of sugar) are real challenges, many patients find that staying connected to the CDG community provides emotional support and practical tips for daily life [14][12]. Your value is not defined by your energy levels; focusing on what you can do, while respecting your body’s limits and keeping your emergency plan updated, is the key to a fulfilling life with PGM1-CDG.
Common questions in this guide
What should a PGM1-CDG emergency letter tell the emergency department?
How can I exercise safely with PGM1-CDG?
What should I do if I get sick with PGM1-CDG?
Is D-galactose a substitute for glucose during low blood sugar?
What does dark urine after exercise mean in PGM1-CDG?
How should teenagers prepare to move from pediatric to adult PGM1-CDG care?
Get notified when new evidence is published on PGM1-CDG.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
News on Clinical Details and Treatment in PGM1-CDG.
Schrapers E, Tegtmeyer LC, Simic-Schleicher G, et al.
JIMD reports 2016; (26()):77-84 doi:10.1007/8904_2015_471.
PMID: 26303607 - 2
Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency.
Preisler N, Cohen J, Vissing CR, et al.
Molecular genetics and metabolism 2017; (122(3)):117-121 doi:10.1016/j.ymgme.2017.08.007.
PMID: 28882528 - 3
Novel insights into the phenotype and long-term D-gal treatment in PGM1-CDG: a case series.
Radenkovic S, Johnsen C, Schulze A, et al.
Therapeutic advances in rare disease 2023; (4()):26330040221150269 doi:10.1177/26330040221150269.
PMID: 37181075 - 4
International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and management.
Altassan R, Radenkovic S, Edmondson AC, et al.
Journal of inherited metabolic disease 2021; (44(1)):148-163 doi:10.1002/jimd.12286.
PMID: 32681750 - 5
Phosphoglucomutase-1 deficiency: Early presentation, metabolic management and detection in neonatal blood spots.
Conte F, Morava E, Bakar NA, et al.
Molecular genetics and metabolism 2020; (131(1-2)):135-146 doi:10.1016/j.ymgme.2020.08.003.
PMID: 33342467 - 6
Phosphoglucomutase-1 deficiency: Intrafamilial clinical variability and common secondary adrenal insufficiency.
Loewenthal N, Haim A, Parvari R, Hershkovitz E
American journal of medical genetics. Part A 2015; (167A(12)):3139-43 doi:10.1002/ajmg.a.37294.
PMID: 26768186 - 7
Successful heart transplantation in an infant with phosphoglucomutase 1 deficiency (PGM1-CDG).
Altassan R, Albert-Brotons DC, Alowain M, et al.
JIMD reports 2023; (64(2)):123-128 doi:10.1002/jmd2.12350.
PMID: 36873091 - 8
The congenital disorder of glycosylation in PGM1 (PGM1-CDG) can cause severe cardiomyopathy and unexpected sudden cardiac death in childhood.
Fernlund E, Andersson O, Ellegård R, et al.
Forensic science international. Genetics 2019; (43()):102111 doi:10.1016/j.fsigen.2019.06.012.
PMID: 31563034 - 9
Oral D-galactose supplementation in PGM1-CDG.
Wong SY, Gadomski T, van Scherpenzeel M, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(11)):1226-1235 doi:10.1038/gim.2017.41.
PMID: 28617415 - 10
A new D-galactose treatment monitoring index for PGM1-CDG.
Perales-Clemente E, Liedtke K, Studinski A, et al.
Journal of inherited metabolic disease 2021; (44(5)):1263-1271 doi:10.1002/jimd.12406.
PMID: 34043239 - 11
Coagulation abnormalities and vascular complications are common in PGM1-CDG.
Radenkovic S, Bleukx S, Engelhardt N, et al.
Molecular genetics and metabolism 2024; (142(4)):108530 doi:10.1016/j.ymgme.2024.108530.
PMID: 38968673 - 12
New Insights into Immunological Involvement in Congenital Disorders of Glycosylation (CDG) from a People-Centric Approach.
Francisco R, Pascoal C, Marques-da-Silva D, et al.
Journal of clinical medicine 2020; (9(7)) doi:10.3390/jcm9072092.
PMID: 32635232 - 13
Pregnancy in a Woman with PGM1-CDG: Longitudinal Metabolic Follow-up During a Lactose-Supported Diet.
Akyüzlüer Güneş MS, Koç Yekedüz M, Sürücü Kara İ, et al.
Journal of clinical research in pediatric endocrinology 2026; doi:10.4274/jcrpe.galenos.2026.2026-7-12.
PMID: 42969211 - 14
CDG Therapies: From Bench to Bedside.
Brasil S, Pascoal C, Francisco R, et al.
International journal of molecular sciences 2018; (19(5)) doi:10.3390/ijms19051304.
PMID: 29702557
This page is for informational purposes only and does not constitute medical advice. Use it with, not instead of, a personalized plan from your metabolic specialist for exercise, sick days, glucose treatment, adrenal support, and emergency care.